Literature DB >> 26277915

CXCL12 and CXCR4 as predictive biomarkers of glioma recurrence pattern after total resection.

W Tang1, X Wang2, Y Chen1, J Zhang1, Y Chen1, Z Lin3.   

Abstract

PURPOSE OF THE STUDY: Previous studies have shown that the pattern of recurrence for glioma is related to the direction of glioma cell invasion. Recent studies demonstrated that the CXCL12/CXCR4 signaling pathway mediates cellular invasion in glioma. Therefore, in this study, we investigated the possible relationship between CXCL12/CXCR4 expression and recurrence pattern in glioma. PATIENTS AND METHODS: Immunohistochemical techniques were used to assess CXCL12/CXCR4 expression in 42 glioma tissues following total resection. According to magnetic resonance imaging (MRI) of gliomas, the recurrence pattern was classified as close or distant pattern. The relationship between recurrence pattern and CXCL12/CXCR4 expression were initially examined by Chi-squared analysis. The prognostic significance of CXCL12 and CXCR4 was determined by log-rank tests and COX proportional hazards model.
RESULTS: CXCL12 was expressed mainly in vascular endothelial cells and CXCR4 was expressed mainly in tumor cells. The recurrence pattern was significantly related to the expression level of CXCL12 in vascular endothelial cells (P=0.002) and CXCR4 in tumor cells (P=0.004). However, CXCL12 and CXCR4 were not independent prognostic factors for progression-free survival or overall survival in glioma patients.
CONCLUSION: The glioma recurrence pattern is related to CXCL12 expression levels in vascular endothelial cells and CXCR4 expression levels in tumor cells; thus, implicating the CXCL12/CXCR4 signaling pathway as a potential target for glioma therapy.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  CXCL12; CXCR4; CXXR4; Gliomas; Gliome; Recurrence pattern; Récidive

Mesh:

Substances:

Year:  2015        PMID: 26277915     DOI: 10.1016/j.patbio.2015.07.002

Source DB:  PubMed          Journal:  Pathol Biol (Paris)        ISSN: 0369-8114


  10 in total

1.  Multifaceted C-X-C Chemokine Receptor 4 (CXCR4) Inhibition Interferes with Anti-Vascular Endothelial Growth Factor Therapy-Induced Glioma Dissemination.

Authors:  Jean-Pierre Gagner; Yasmeen Sarfraz; Valerio Ortenzi; Fawaz M Alotaibi; Luis A Chiriboga; Awab T Tayyib; Garry J Douglas; Eric Chevalier; Barbara Romagnoli; Gérald Tuffin; Michel Schmitt; Guillaume Lemercier; Klaus Dembowsky; David Zagzag
Journal:  Am J Pathol       Date:  2017-07-20       Impact factor: 4.307

2.  Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas.

Authors:  Chongxian Hou; Yukitomo Ishi; Hiroaki Motegi; Michinari Okamoto; Yafei Ou; Jiawei Chen; Shigeru Yamaguchi
Journal:  J Neurooncol       Date:  2019-09-10       Impact factor: 4.130

3.  Neuroimaging classification of progression patterns in glioblastoma: a systematic review.

Authors:  Rory J Piper; Keerthi K Senthil; Jiun-Lin Yan; Stephen J Price
Journal:  J Neurooncol       Date:  2018-03-30       Impact factor: 4.130

4.  miR-137 acts as a tumor suppressor via inhibiting CXCL12 in human glioblastoma.

Authors:  Dehua Li; Wei Shan; Yan Fang; Pan Wang; Jicheng Li
Journal:  Oncotarget       Date:  2017-08-24

Review 5.  A meta-analysis of CXCL12 expression for cancer prognosis.

Authors:  Harsh Samarendra; Keaton Jones; Tatjana Petrinic; Michael A Silva; Srikanth Reddy; Zahir Soonawalla; Alex Gordon-Weeks
Journal:  Br J Cancer       Date:  2017-05-23       Impact factor: 7.640

Review 6.  The Role of Selected Chemokines and Their Receptors in the Development of Gliomas.

Authors:  Magdalena Groblewska; Ala Litman-Zawadzka; Barbara Mroczko
Journal:  Int J Mol Sci       Date:  2020-05-24       Impact factor: 5.923

Review 7.  Potential Role of CXCR4 Targeting in the Context of Radiotherapy and Immunotherapy of Cancer.

Authors:  Franziska Eckert; Karin Schilbach; Lukas Klumpp; Lilia Bardoscia; Efe Cumhur Sezgin; Matthias Schwab; Daniel Zips; Stephan M Huber
Journal:  Front Immunol       Date:  2018-12-21       Impact factor: 7.561

8.  CIRP regulates BEV-induced cell migration in gliomas.

Authors:  Yu-Xiao Liu; Jun-Nian Zhou; Ke-Hui Liu; Xiang-Pin Fu; Zhi-Wen Zhang; Qin-Hong Zhang; Wen Yue
Journal:  Cancer Manag Res       Date:  2019-03-11       Impact factor: 3.989

Review 9.  The Role of the CXCL12/CXCR4/ACKR3 Axis in Autoimmune Diseases.

Authors:  Eva M García-Cuesta; César A Santiago; Jesús Vallejo-Díaz; Yasmina Juarranz; José Miguel Rodríguez-Frade; Mario Mellado
Journal:  Front Endocrinol (Lausanne)       Date:  2019-08-27       Impact factor: 5.555

10.  Establishment of primary cell culture and an intracranial xenograft model of pediatric ependymoma: a prospect for therapy development and understanding of tumor biology.

Authors:  Lorena Favaro Pavon; Tatiana Tais Sibov; Silvia Regina Caminada de Toledo; Daniela Mara de Oliveira; Francisco Romero Cabral; Jean Gabriel de Souza; Pamela Boufleur; Luciana C Marti; Jackeline Moraes Malheiros; Edgar Ferreira da Cruz; Fernando F Paiva; Suzana M F Malheiros; Manoel A de Paiva Neto; Alberto Tannús; Sérgio Mascarenhas de Oliveira; Nasjla Saba Silva; Andrea Maria Cappellano; Antonio Sérgio Petrilli; Ana Marisa Chudzinski-Tavassi; Sérgio Cavalheiro
Journal:  Oncotarget       Date:  2018-04-24
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.